CancerCare Manitoba, 675 McDermot Avenue (MDSTEELE.MB.CA)
An additional $4 million is being provided to CancerCare Manitoba by the province for the provision of cancer drugs.
The funding to the Provincial Oncology Drug Program will benefit cancer patients provincewide.
“Cancer is the leading cause of death in Manitoba. However, thanks to research, innovative treatments and new drugs, the cure rate for cancer is steadily improving,” said Dr. Sri Navaratnam, president and CEO of CancerCare Manitoba.
“We are very lucky that Manitobans with cancer are able to receive the intravenous drugs they need, whether at CancerCare, at regional cancer hubs or in their own home, at no cost to them.”
The additional funding brings the budgeted amount for providing intravenous cancer drugs in Manitoba to approximately $50 million annually.
